Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, Gansu Province, China.
Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou 730030, Gansu Province, China.
Biosci Rep. 2019 Jan 18;39(1). doi: 10.1042/BSR20180618. Print 2019 Jan 31.
A consensus about the prognostic role of NIMA-related kinase 2 (NEK2) expression in various solid tumors has not been made yet. Thus, this meta-analysis aimed to systematically assess the prognostic role of NEK2 expression in patients with solid tumors. The eligible studies were identified through searching PubMed, Web of Science, and EMBASE. The hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) were used to evaluate the link between NEK2 overexpression and overall survival (OS) and disease-free survival/recurrence-free survival (DFS/RFS) of patients with solid tumors. A total of 17 studies with 4897 patients were included in this meta-analysis. Among these studies, all of them explored the association between NEK2 expression and OS of patients with solid tumors. Our pooled analysis indicated that NEK2 overexpression was significantly related to adverse OS (HR = 1.66; 95% CI: 1.38-2.00; = 0.001). Additionally, there were six studies with 854 patients that investigated the association between NEK2 expression and DFS/RFS. Our pooled result indicated that there was a substantial relationship between NEK2 overexpression and poorer DFS/RFS (HR = 2.00; 95% CI: 1.61-2.48; = 0.003). In conclusion, our meta-analysis indicated that NEK2 may be a useful predictor of prognosis and an effective therapeutic target in solid tumors. Nevertheless, more high-quality studies are warranted to further support our conclusions because of several limitations in our meta-analysis.
关于丝氨酸/苏氨酸激酶 NIMA 相关激酶 2（NEK2）在各种实体瘤中的预后作用尚未达成共识。因此，本荟萃分析旨在系统评估 NEK2 表达在实体瘤患者中的预后作用。通过检索 PubMed、Web of Science 和 EMBASE 确定了符合条件的研究。使用风险比（HRs）及其相应的 95%置信区间（CIs）来评估 NEK2 过表达与实体瘤患者的总生存期（OS）和无病生存/无复发生存（DFS/RFS）之间的关系。本荟萃分析共纳入了 17 项研究，共 4897 名患者。这些研究中，均探讨了 NEK2 表达与实体瘤患者 OS 的关系。我们的汇总分析表明，NEK2 过表达与不良 OS 显著相关（HR = 1.66；95%CI：1.38-2.00； = 0.001）。此外，有 6 项研究，共 854 名患者，探讨了 NEK2 表达与 DFS/RFS 的关系。我们的汇总结果表明，NEK2 过表达与较差的 DFS/RFS 显著相关（HR = 2.00；95%CI：1.61-2.48； = 0.003）。总之，我们的荟萃分析表明，NEK2 可能是实体瘤预后的有用预测指标和有效的治疗靶点。然而，由于我们的荟萃分析存在一些局限性，需要更多高质量的研究来进一步支持我们的结论。
